Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 12 versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 12 versus METHADOSE.
FENTANYL-12 vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Transdermal: 12 mcg/hour applied every 72 hours. For opioid-tolerant patients only.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults. Prolonged in elderly, hepatic impairment, and obesity (up to 20 hours). Context: half-life increases with continuous infusion (context-sensitive half-life).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Primarily hepatic metabolism (N-dealkylation and hydroxylation) with <10% excreted unchanged in urine. Renal excretion accounts for ~75% of total elimination as metabolites; fecal excretion ~9%.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist